The effect of IL-6 on cancer has long been recognised, with evidence showing that it induces higher proliferation and EMT changes in ovary cancers, breast cancers, and HNSCC [7,20], as well as promoting an immunosuppressive TME [49]. Here, IL6 is linked to head and neck squamous cell carcinoma.